Natco Pharma Approves ₹1279 Crore Rights Issue

Scrip Code(s): 524816 (BSE)

Document Title: Outcome of the meeting of the Board of Directors

Key Financial Disclosures

Type of Issue:

Type: Rights Issue

Amount to be Raised: ₹12,79,35,61,500 (Rupees One Thousand Two Hundred and Seventy Nine Crores Thirty Five Lakhs Sixty One Thousand Five Hundred only)

Terms and Structure of the Issue:

• Face Value: ₹2 per equity share
• Issue Price: ₹750 per Rights Equity Share (including a premium of ₹748 per share)
• Total Number of Shares: 1,70,58,082 Rights Equity Shares
• Entitlement Ratio: 2 Rights Equity Shares for every 21 fully paid-up Equity Shares held on record date
• Record Date: October 1, 2026
• Rights Issue Opening Date: Monday, 12th October, 2026
• Rights Issue Closing Date: Thursday, 22nd October, 2026
• On-market renunciation period: Monday, 12th October, 2026 to Friday, 16th October, 2026
• ISIN for rights entitlements: INE987B20018

Outstanding Equity Shares:

• Prior to Rights Issue: 17,91,09,870 equity shares
• Post Rights Issue (assuming full subscription): 19,61,67,952 equity shares

Fractional Entitlement Treatment:

• Shareholders holding less than 21 Equity Shares have 'zero' Rights Entitlement
• Fractional entitlements are ignored in computation
• Eligible shareholders with fractional entitlements get preferential consideration for one additional Rights Equity Share if they apply for additional shares
• Shareholders with less than 21 shares can apply for additional Rights Equity Shares and get preference for one additional share

Rights Equity Shares in Abeyance:

• Shares under dispute, court proceedings, transmission, or in demat suspense accounts will have Rights Entitlement held in abeyance
• Application forms and Rights Entitlement letters will not be dispatched for these cases
• Resolution requires submission of documents confirming legal ownership by closing date

Board/Committee Decisions

Decisions made by the Board:

• Approved the rights issue of equity shares for up to ₹12,79,35,61,500
• Approved all terms and conditions of the rights issue including pricing, record date, and issue period
• Approved amendment to the Code of Conduct to regulate, monitor and report trading by designated persons

Other Noteworthy Updates:

• Board meeting commenced at 10:30 a.m. and completed at 11:00 a.m. on September 25, 2026
• Amendment to Code of Conduct will be available on company website at https://www.natcopharma.co.in/investor-relations/policies
• This intimation is issued under Regulations 30 and 42 of SEBI Listing Regulations